Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

58.87 +0.64 (+1.10%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
66 67 Next >
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:BPTH),(NASDAQ:LGVN),(NASDAQ:SLS),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade
Their prices might not be done falling, but you can count on the dividends they distribute to continue rising steadily. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 High-Yield Dividend Stocks for Income Now and Growth Later
Buying high-yield dividend stocks at a low price today gives you current income with the opportunity for growth when interest rates come down later this year 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Bristol-Myers Squibb's Options Frenzy: What You Need to Know
Via Benzinga
Smart Money Is Betting Big In BMY Options
Via Benzinga
6% Yield Bristol Myers Squibb Value Trap Or Long-Term Opportunity?
BMY is offering a 6% yield and trading for less than 9 times earnings. 
Via Talk Markets
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
From FN Media Group LLC
Via GlobeNewswire
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
From Bristol Myers Squibb
Via Business Wire
Bristol-Myers Squibb's Options: A Look at What the Big Money is Thinking
Via Benzinga
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
These penny stocks to buy provide a good opportunity for investors to buy low-priced stocks that provide significant growth potential. 
Via InvestorPlace
7 Stocks Warren Buffett Has Sold in the Past Year (and You Should Too)
Here are seven Warren Buffett stocks to sell that the Oracle himself has decided that they've lost their luster. 
Via InvestorPlace
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent... 
Via Talk Markets
The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024
Undervalued stocks under $50 hold significant appeal, but as every investor knows, value is in the eye of the beholder 
Via InvestorPlace
FDA Approves Geron's First Commercial Drug, Competes With Bristol Myers Squibb's Blood Cancer Drug
FDA approves Geron's Rytelo (imetelstat) for adults with low-to intermediate-1 risk myelodysplastic syndromes and transfusion-dependent anemia Geron's first commercial treatment targets a market... 
Via Benzinga
Exposures Product Safety
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
Replimune reported that the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma showed a 33.6% response rate, with all responses lasting over six months. The treatment was... 
Via Benzinga
Bristol Myers Squibb Announces Phase 3 Results Of Opdivo/Yervoy Combo In Liver Cancer Patients
Opdivo plus Yervoy combo shows significant survival benefits and higher response rates vs. lenvatinib/sorafenib in HCC. 
Via Benzinga
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Why US Drug Giant Bristol Myers Squibb Stock Trading Up On Monday
Bristol Myers Squibb's KRYSTAL-12 study reveals Krazati's significant benefits over chemotherapy for KRASG12C-mutated NSCLC, improving progression-free survival and response rates. 
Via Benzinga
Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
2 No-Brainer Dividend Stocks You Can Buy With $100 in June
This pair of high-yield dividend payers offer yields near 6% and a chance for steady payout raises in the years to come. 
Via The Motley Fool
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
FDA Expands Approval For Bristol Myers Squibb's Breyanzi, Making CAR T Cell Therapy Available For Broadest Range Of B-Cell Malignancies
FDA approves Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) for relapsed or refractory mantle cell lymphoma, marking its fourth non-Hodgkin lymphoma subtype indication. 
Via Benzinga
Exposures Product Safety
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
From Bristol Myers Squibb
Via Business Wire
7 Underappreciated Stocks With 25% Return Potential in 2024
Each of these underappreciated stocks is expected to provide 25%+ returns this year, which is reason enough to pay attention. 
Via InvestorPlace
Are Boomers Crashing The Economy Or Saving It? Why Investors Are Perplexed And What You Can Do To Prepare
Mass retirement of boomers could have major economic impact. Experts anticipate both risks and opportunities from the largest wealth transfer in history. 
Via Benzinga
Topics Economy Retirement
Exposures Economy Pension
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
From Bristol Myers Squibb
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
66 67 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.